HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CFM6104

structure in first source

Also Known As:

N-((5-(2-(2-(1h-imidazol-1-yl)ethyl)-2h-indazol-3-yl)-1,2,4-oxadiazol-3-yl)methyl)-3-methylbenzamide

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Al-Izki, Sarah: 1 article (01/2014)
2.	Amor, Sandra: 1 article (01/2014)
3.	Baker, David: 1 article (01/2014)
4.	Browne, Lorcan: 1 article (01/2014)
5.	Clutterbuck, Lisa: 1 article (01/2014)
6.	Edith Chan, A W: 1 article (01/2014)
7.	Garthwaite, John: 1 article (01/2014)
8.	Gerritsen, Wouter H: 1 article (01/2014)
9.	Giovannoni, Gavin: 1 article (01/2014)
10.	Hankey, Deborah J R: 1 article (01/2014)

Related Diseases

1.	Multiple Sclerosis 01/01/2014 - "This was assessed in the relapsing-progressive experimental autoimmune encephalomyelitis ABH mouse model of multiple sclerosis using conventional sodium channel blockers and a novel central nervous system-excluded sodium channel blocker (CFM6104) that was synthesized with properties that selectively target the inflammatory penumbra in experimental autoimmune encephalomyelitis lesions. "
2.	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/01/2014 - "CFM6104 significantly slowed down the accumulation of disability and nerve loss in experimental autoimmune encephalomyelitis. " 01/01/2014 - "This was assessed in the relapsing-progressive experimental autoimmune encephalomyelitis ABH mouse model of multiple sclerosis using conventional sodium channel blockers and a novel central nervous system-excluded sodium channel blocker (CFM6104) that was synthesized with properties that selectively target the inflammatory penumbra in experimental autoimmune encephalomyelitis lesions. "

Related Drugs and Biologics

1.	Sodium Channel Blockers